Department of Rehabilitation Medicine (Jianhua), Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China.
School of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan, China.
Trials. 2024 Sep 18;25(1):616. doi: 10.1186/s13063-024-08407-z.
Rotator cuff calcific tendinitis (RCCT) is a common shoulder disease whose main symptoms include shoulder pain, limited mobility, and calcification deposits in the shoulder. Traditional treatment methods have certain limitations, so finding new treatment methods has become the focus of research. Extracorporeal shock wave (ESW) and platelet-rich plasma (PRP) treatments have attracted much attention due to their non-invasive and tissue repair-promoting properties; however, the efficacy of their combined treatment in RCCT remains unclear.
This study is designed as a single-center, assessment-blind, randomized controlled clinical trial with three parallel groups. Sixty subjects will be recruited and randomly divided into the ESW group, PRP group, and ESW combined with PRP group, in a 1:1:1 ratio. The entire intervention period is 4 weeks, and the follow-up period is 4 weeks. Outcomes will be measured at baseline (T0), after 1 week of intervention (T1), after 2 weeks of intervention (T2), after 4 weeks of intervention (T3), and after an additional 4 weeks of follow-up period (T4). The primary endpoint is the VAS score. Secondary endpoints are ASES, CMS, UCLA, and the location and size of calcified areas.
This study aims to evaluate the efficacy of ESW therapy combined with PRP in treating RCCT. We compare the effects of single and combined treatments to explore their impact on disease symptoms, functional improvement, and calcification regression. This provides a scientific basis for identifying more effective treatment options.
ClinicalTrials.gov NCT06372600. Registered on April 17, 2024; version 1.
肩袖钙化性肌腱炎(RCCT)是一种常见的肩部疾病,主要症状包括肩部疼痛、活动受限和肩部钙化沉积。传统的治疗方法存在一定的局限性,因此寻找新的治疗方法成为研究的重点。体外冲击波(ESW)和富血小板血浆(PRP)治疗因其具有非侵入性和促进组织修复的特性而受到广泛关注;然而,它们联合治疗 RCCT 的疗效尚不清楚。
本研究设计为单中心、评估盲、随机对照临床试验,设三个平行组。将招募 60 名受试者,按照 1:1:1 的比例随机分为 ESW 组、PRP 组和 ESW 联合 PRP 组。整个干预期为 4 周,随访期为 4 周。在基线(T0)、干预后 1 周(T1)、干预后 2 周(T2)、干预后 4 周(T3)和额外随访 4 周(T4)时测量结局。主要终点是 VAS 评分。次要终点是 ASES、CMS、UCLA 和钙化区域的位置和大小。
本研究旨在评估 ESW 联合 PRP 治疗 RCCT 的疗效。我们比较了单一和联合治疗的效果,以探讨它们对疾病症状、功能改善和钙化消退的影响。这为确定更有效的治疗方案提供了科学依据。
ClinicalTrials.gov NCT06372600。于 2024 年 4 月 17 日注册;版本 1。